Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM)

Blood (2014) 124 (21): 4773.

https://doi.org/10.1182/blood.V124.21.4773.4773

Published: 2014

Journal Articles

Clinical Characteristics and Treatment Outcomes in Patients Diagnosed with Primary Mediastinal Large B-Cell Lymphoma at Princess Margaret Cancer Centre from 1994-2012

Anna M. Dyszkiewicz-Korpanty, MD PhD, Manjula Maganti, David C. Hodgson, MD, John G. Kuruvilla, MD, Vishal Kukreti, MD, Rodger E. Tiedemann, MD PhD, Alexander Sun, MD, Richard Tsang, MD, Mary Gospodarowicz, MD, Melania Pintilie, Anna Porwit, MDPhD, Michael Crump, MD

Blood (2014) 124 (21): 4447.

https://doi.org/10.1182/blood.V124.21.4447.4447

Published: 2014

Journal Articles

Outcome of 17p Deleted Multiple Myeloma (MM) in the Era of Novel Agents and Tandem Transplantation: A Single Centre Experience

Gurdeep Parmar, MDFRACP, Esther Masih-khan, PhD, Eshetu G Atenafu, MSc, Donna E. Reece, MD, Suzanne Trudel, MD, Rodger E. Tiedemann, MD PhD, Vishal Kukreti, MD, Christine I. Chen, MD MD FRCPC

Blood (2014) 124 (21): 4756.

https://doi.org/10.1182/blood.V124.21.4756.4756

Published: 2014

Journal Articles

The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL)

Blood (2014) 124 (21): 396.

https://doi.org/10.1182/blood.V124.21.396.396

Published: 2014

Journal Articles

A Phase 2 Study Of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) For Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy: Waldenström’s Macroglobulinemia Cohort Results

Blood (2013) 122 (21): 4352.

https://doi.org/10.1182/blood.V122.21.4352.4352

Published: 2013

Journal Articles

Early Relapse After Single ASCT For MM Patients Is a Major Predictor Of Survival In The Era Of Novel Agents

Victor H Jimenez Zepeda, MD, Suzanne Trudel, MD, MSC, FRCPC, Donna E. Reece, MD, Christine I. Chen, MD, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Norman Franke, MD, Andrew Winter, Sr., RN, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 3396.

https://doi.org/10.1182/blood.V122.21.3396.3396

Published: 2013

Journal Articles

Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) For The Treatment Of Secondary Plasma Cell Leukaemia

Victor H Jimenez Zepeda, MD, Donna E. Reece, MD, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD PhD FRACP, FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 5398.

https://doi.org/10.1182/blood.V122.21.5398.5398

Published: 2013

Journal Articles

Outcome Of t(4;14) In Multiple Myeloma - Princess Margaret Cancer Centre Experience Over The Last 10 Years

Sophia Farooki, MD, FRCPC, Manjula Maganti, Donna E Reece, MD, FRCPC, Esther Masih-Khan, PhD, Victor H Jimenez-Zepeda, MD, PD, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 5315.

https://doi.org/10.1182/blood.V122.21.5315.5315

Published: 2013

Journal Articles

Absolute Lymphocyte Count At Day+15 and +30 Post-ASCT As Predictors of Early and 1-Year Mortality for Patients with AL Amyloidosis Treated with a Single Autologous Stem Cell Transplant

Victor Hugo Jimenez-Zepeda, MD PD, Donna Reece, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Norman Franke, MD, Andrew Winter, Sr., RN, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD

Blood (2012) 120 (21): 4518.

https://doi.org/10.1182/blood.V120.21.4518.4518

Published: 2012

Journal Articles

Monoclonal and Oligoclonal Bands After Single Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: Impact On Overall Survival and Progression-Free Survival

Victor Hugo Jimenez-Zepeda, MD, Norman Franke, MD, Andrew Winter, Sr., RN, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD, PhD FRACP FRCPA, Vishal Kukreti, MD

Blood (2012) 120 (21): 595.

https://doi.org/10.1182/blood.V120.21.595.595

Published: 2012

Journal Articles

Botezomib Containing Regimens Provide a Rapid Hematological and Cardiac Response in Patients with AL Amyloidosis

Victor H Jimenez-Zepeda, MD, PD, Donna Reece, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD, PhD, FRACP, FRCPA, Vishal Kukreti, MD

Blood (2012) 120 (21): 4064.

https://doi.org/10.1182/blood.V120.21.4064.4064

Published: 2012

Journal Articles

Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,

Donna E. Reece, MD, FRCPC, Giovanni Piza Rodriguez, MD, David Szwajcer, MD, FRCPC, Leonard A Minuk, MD, FRCPC, Mariela Pantoja, MSc, PhD, Andrew Belch, MD, Chaim Shustik, MD, Julie Stakiw, MD, Darrell J. White, MD, Christine Chen, MD, MSC, FRCPC, Vishal Kukreti, MD, FRCPC, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Michael Sebag, MD, PhD, Gayle Jenkins, Nizar J Bahlis, MD, Lisa W Le, MSc, Suzanne Trudel, MD

Blood (2011) 118 (21): 3982.

https://doi.org/10.1182/blood.V118.21.3982.3982

Published: 2011

Journal Articles

Central Nervous System (CNS) Involvement with Multiple Myeloma (MM) – Longterm Survival Can Be Achieved with Radiation, Intrathecal (IT) Chemotherapy, and Immunomodulatory Agents (IMiDs),

Christine Chen, MD, MEd, FRCPC, Ahmed M. Rabea, MD, Esther Masih-Khan, PhD, Chia-Min Chu, Vishal Kukreti, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Donna E. Reece, MD, FRCPC

Blood (2011) 118 (21): 3983.

https://doi.org/10.1182/blood.V118.21.3983.3983

Published: 2011

Journal Articles

ERN1/IRE1 and XBP1 Are Dispensable for Myeloma Cell Survival but Are Required for the Anti-Myeloma Activity of Bortezomib

Chungyee Leung-Hagesteijn, MSc, Brad Wouters, PhD, Rodger E. Tiedemann, MD PhD FRACP FRCPA

Blood (2011) 118 (21): 986.

https://doi.org/10.1182/blood.V118.21.986.986

Published: 2011

Journal Articles

Very Good Partial Response and Complete Response Predict Superior Overall Survival and Progression Free Survival After Single Autologous Stem Cell Transplant in Patients with Multiple Myeloma,

Victor H Jimenez-Zepeda, MD, PD, Donna E. Reece, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Christine Chen, MD, Andrew Winter, Sr., RN, Norman Franke, MD, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2011) 118 (21): 4111.

https://doi.org/10.1182/blood.V118.21.4111.4111

Published: 2011

Journal Articles

Absolute Lymphocyte Count As Predictor of Overall Survival for Patients with Multiple Myeloma Treated with Single Autologous Stem Cell Transplant: Experience of a Single Centre,

Victor H Jimenez-Zepeda, MD, PD, Donna E. Reece, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Christine Chen, MD, Norman Franke, MD, Andrew Winter, Sr., RN, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2011) 118 (21): 4121.

https://doi.org/10.1182/blood.V118.21.4121.4121

Published: 2011

Journal Articles

CYBOR-D Induction Therapy In Clinical Practice

Christine Chen, MD, Esther Masih-Khan, PhD, Victor Jimenez-Zepeda, MD, Donna E. Reece, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2011) 118 (21): 5136.

https://doi.org/10.1182/blood.V118.21.5136.5136

Published: 2011

Journal Articles

Kinome and Druggable Genome Vulnerabilities in Multiple Myeloma Identified by Systematic RNA Interference Screening.

Rodger E. Tiedemann, MD, PhD, Yuan-Xiao Zhu, PhD, Holly Yin, PhD, Quick Que, PhD, Chang-Xin Shi, PhD, Spyro Mousses, PhD, Keith Stewart, MD

Blood (2007) 110 (11): 391.

https://doi.org/10.1182/blood.V110.11.391.391

Published: 2007

Journal Articles

PRL3 Is a Mediator of IL6/STAT3 Signaling and Defines a Population of Multiple Myeloma Patients Distinct from Those That Activate NFkB.

Michael Sebag, MD, PhD, Keith Stewart, MD, Chang-Xin Shi, PhD, Yuan-Xiao Zhu, PhD, Wee-Joo Chng, MD, Jonathan Keats, PhD, Rodger E. Tiedemann, MD, PhD, Rafael Fonseca, MD, Marta Chesi, PhD, Peter Leif Bergsagel, MD

Blood (2007) 110 (11): 671.

https://doi.org/10.1182/blood.V110.11.671.671

Published: 2007

Journal Articles

Chemical Library Screening Identifies Novel Inhibitors of Cyclin D2 ( CCND2) Transactivation That Selectively Induce Apoptosis in Multiple Myeloma Cells.

Rodger E. Tiedemann, MD, PhD, Xinliang Mao, PhD, Chng-Xin Shi, PhD, Yuan Xiao Zhang, PhD, Stephen Palmer, Craig B. Reeder, MD, Aaron Schimmer, MD, Keith Stewart, MD

Blood (2006) 108 (11): 3421.

https://doi.org/10.1182/blood.V108.11.3421.3421

Published: 2006

NARROW

Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM)

Clinical Characteristics and Treatment Outcomes in Patients Diagnosed with Primary Mediastinal Large B-Cell Lymphoma at Princess Margaret Cancer Centre from 1994-2012

Outcome of 17p Deleted Multiple Myeloma (MM) in the Era of Novel Agents and Tandem Transplantation: A Single Centre Experience

The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL)

A Phase 2 Study Of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) For Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy: Waldenström’s Macroglobulinemia Cohort Results

Early Relapse After Single ASCT For MM Patients Is a Major Predictor Of Survival In The Era Of Novel Agents

Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) For The Treatment Of Secondary Plasma Cell Leukaemia

Outcome Of t(4;14) In Multiple Myeloma - Princess Margaret Cancer Centre Experience Over The Last 10 Years

Absolute Lymphocyte Count At Day+15 and +30 Post-ASCT As Predictors of Early and 1-Year Mortality for Patients with AL Amyloidosis Treated with a Single Autologous Stem Cell Transplant

Monoclonal and Oligoclonal Bands After Single Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: Impact On Overall Survival and Progression-Free Survival

Botezomib Containing Regimens Provide a Rapid Hematological and Cardiac Response in Patients with AL Amyloidosis

Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,

Central Nervous System (CNS) Involvement with Multiple Myeloma (MM) – Longterm Survival Can Be Achieved with Radiation, Intrathecal (IT) Chemotherapy, and Immunomodulatory Agents (IMiDs),

ERN1/IRE1 and XBP1 Are Dispensable for Myeloma Cell Survival but Are Required for the Anti-Myeloma Activity of Bortezomib

Very Good Partial Response and Complete Response Predict Superior Overall Survival and Progression Free Survival After Single Autologous Stem Cell Transplant in Patients with Multiple Myeloma,

Absolute Lymphocyte Count As Predictor of Overall Survival for Patients with Multiple Myeloma Treated with Single Autologous Stem Cell Transplant: Experience of a Single Centre,

CYBOR-D Induction Therapy In Clinical Practice

Kinome and Druggable Genome Vulnerabilities in Multiple Myeloma Identified by Systematic RNA Interference Screening.

PRL3 Is a Mediator of IL6/STAT3 Signaling and Defines a Population of Multiple Myeloma Patients Distinct from Those That Activate NFkB.

Chemical Library Screening Identifies Novel Inhibitors of Cyclin D2 ( CCND2) Transactivation That Selectively Induce Apoptosis in Multiple Myeloma Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only